The best next drug in the course of generalized anxiety disorders: the "PN-GAD-algorithm"

被引:4
作者
Linden, Michael [1 ]
Bandelow, Borwin [2 ]
Boerner, Reinhard Joachim [3 ]
Brasser, Matthias [4 ]
Kasper, Siegfried [5 ]
Moeller, Hans-Juergen [6 ]
Pyrkosch, Lena [1 ]
Volz, Hans-Peter [7 ]
Wittchen, Hans-Ulrich [8 ]
机构
[1] Charite, Res Grp Psychosomat Rehabil, D-13353 Berlin, Germany
[2] Univ Gottingen, Dept Psychiat & Psychotherapy, D-37073 Gottingen, Germany
[3] Christian Hosp Quakenbruck GmbH, Ctr Psychol & Psychosocial Med, Quakenbruck, Germany
[4] Pfizer Pharma GmbH, Med Affairs, Berlin, Germany
[5] Med Univ Vienna, Dept Psychiat & Psychotherapy, Vienna, Austria
[6] Univ Munich, Dept Psychiat & Psychotherapy, Munich, Germany
[7] Hosp Psychiat Psychotherapy & Psychosomat Med Sch, Werneck, Germany
[8] Tech Univ Dresden, Inst Clin Psychol & Psychotherapy, Dresden, Germany
关键词
Generalized anxiety disorder; drug selection; treatment algorithm; PN-algorithm; shared decision-making; VENLAFAXINE EXTENDED-RELEASE; PLACEBO-CONTROLLED TRIAL; LONG-TERM TREATMENT; SEROTONIN REUPTAKE INHIBITORS; DOUBLE-BLIND EVALUATION; PRIMARY-CARE; PHARMACOLOGICAL-TREATMENT; NONDEPRESSED OUTPATIENTS; NATIONAL-COMORBIDITY; PAROXETINE TREATMENT;
D O I
10.3109/13651501.2012.722645
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Objective. Today, there are many pharmacotherapeutic options for generalized anxiety disorder (GAD). The question is, which is the best medication for a particular patient at a particular moment? This is especially challenging because GAD is by definition a chronic disorder and new interventions should learn from earlier experiences. An algorithm which can help to use pretreatment information for drug selection is the "Pretreatment - Next Treatment (PN) - Algorithm". This article introduces an PN-algorithm for GAD. Methods and results. For the development of a GAD-specific PN-algorithm, all possible pharmacological options for GAD are reviewed and brought into a rank order on the basis of scientific evidence regarding efficacy, tolerability, or price: (1) pregabalin, (2) venlafaxine XR, (3) selective serotonin reuptake inhibitors, (4) tricyclic antidepressants, (5) buspirone, (6) antipsychotics, (7) benzodiazepines, and (8) hydroxyzine. Based on this hierarchy and patient-specific information, a decision algorithm is derived, which allows to assess and evaluate pretreatment and to select the drug with no contraindications, limited negative or convincing positive effects, or the option which has not been used so far but which is the next compound in the hierarchy. Conclusions. The "PN-GAD-algorithm" can be easily translated into a checklist to support clinical decision-making. It can also help to increase patient empowerment and cooperation in long-term treatment.
引用
收藏
页码:78 / 89
页数:12
相关论文
共 149 条
[1]  
ACHBERGER M, 1998, PSYCHIAT DANUB, V10, P373
[2]   Valproate (depakine-chrono) in the acute treatment of outpatients with generalized anxiety disorder without psychiatric comorbidity: Randomized, double-blind placebo-controlled study [J].
Aliyev, Nadir A. ;
Aliyev, Zafar N. .
EUROPEAN PSYCHIATRY, 2008, 23 (02) :109-114
[3]   A non-inferiority comparison of duloxetine and venlafaxine in the treatment of adult patients with generalized anxiety disorder [J].
Allgulander, C. ;
Nutt, D. ;
Detke, M. ;
Erickson, J. ;
Spann, M. ;
Walker, D. ;
Ball, S. G. ;
Russell, J. M. .
JOURNAL OF PSYCHOPHARMACOLOGY, 2008, 22 (04) :417-425
[4]   WCA-recommendations for the long-term treatment of generalized anxiety disorder [J].
Allgulander, C ;
Bandelow, B ;
Hollander, E ;
Montgomery, SA ;
Nutt, DJ ;
Okasha, A ;
Pollack, MH ;
Stein, DJ ;
Swinson, RP .
CNS SPECTRUMS, 2003, 8 (08) :53-61
[5]   Venlafaxine extended release (ER) in the treatment of generalised anxiety disorder - Twenty-four-week placebo-controlled dose-ranging study [J].
Allgulander, C ;
Hackett, D ;
Salinas, E .
BRITISH JOURNAL OF PSYCHIATRY, 2001, 179 :15-22
[6]  
Allgulander C, 1998, PSYCHOPHARMACOL BULL, V34, P165
[7]  
*AM PSYCH ASS TASK, 1990, BENZ DEP TOX AB TASK
[8]  
[Anonymous], CURRENT PSYCHOPHARMA
[9]   CONTROLLED COMPARISON OF THE EFFICACY AND SAFETY OF 4 DOSES OF SURICLONE, DIAZEPAM, AND PLACEBO IN GENERALIZED ANXIETY DISORDER [J].
ANSSEAU, M ;
OLIE, JP ;
VONFRENCKELL, R ;
JOURDAIN, G ;
STEHLE, B ;
GUILLET, P .
PSYCHOPHARMACOLOGY, 1991, 104 (04) :439-443
[10]  
ANSSEAU M, 1991, NEUROPSYCHOBIOLOGY, V24, P74